Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:00 PM
Ignite Modification Date:
2025-12-24 @ 5:00 PM
NCT ID:
NCT04862650
Eligibility Criteria:
Inclusion Criteria:
* Recurrent/metastatic (R/M) SCCHN of the oral cavity, oropharynx, larynx and hypopharynx
* No prior systemic therapy for treatment of R/M disease
* Patients with squamous cell carcinoma of an unknown primary are eligible provided their tumor tested positive for p-16 and they have previously received treatment for locoregional head and neck cancer
* Must be at least four weeks since prior radiation and/or surgery
* Must be at least four weeks from curative intent systemic therapy. Of note: patients who have received up to two courses of chemoradiotherapy (CRT) for locoregionally advanced disease are eligible. Induction chemotherapy will not be considered a separate line of therapy
* At least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)
* 18 years of age and older
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* White blood cell (WBC) count \> 2,500 cells/uL
* Absolute neutrophil count (ANC) \>1,500 cells/uL
* Platelet count \>= 100,000 cells/uL
* Hemoglobin \>= 9 g/dL
* Creatinine =\< 1.6 mg/dL
* Total bilirubin =\< 1.6 mg/dL
* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase \[AST\]), serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 2.5 x upper limit of normal (ULN)
* Potassium \>= lower limit of normal (LLN)
* Willingness to use medically acceptable contraception throughout the study period and four months after the final administration of treatment
* For female subjects with reproductive potential: a negative serum pregnancy test at baseline
* Ability and willingness to provide written informed consent and to comply with the study visits and assessment schedule
Exclusion Criteria:
* Disease amenable to curative local therapy
* Nasopharyngeal, salivary gland, lip, or sinonasal carcinoma
* Disease that requires corticosteroids or other ongoing immunosuppressive treatment
* Previous treatment with mAb-based immunotherapy for treatment of prior oncologic treatment
* Previous treatment with PI3K inhibitors
* Known brain metastases, unless stable for at least 21 days prior to registration
* Known infection human immunodeficiency virus (HIV), hepatitis B or C
* Clinically significant cardiac disease (e.g., congestive heart failure, unstable or uncontrolled angina, myocardial infarction) within the past six months
* History of pneumonitis within the past five years
* Recipient of live vaccines (including attenuated) within 30 days of planned study treatment
* Female patients who are pregnant or breast-feeding
* Any other condition or circumstance that could interfere with adherence to the study's procedures or requirements or otherwise compromise the study's objectives in the opinion of the Principal Investigator
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04862650
Study Brief:
Protocol Section:
NCT04862650